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Abstract   
 
Background:  Cervical cancer remains a leading cause of morbidity and mortality for 
women worldwide.  Cytological methods of screening introduced over 50 years ago 
remain the primary screening method.  With advancing science and the understanding of 
the etiology of cervical cancer, new methods of screening have been introduced such as 
HPV DNA and HPV mRNA testing.  This review of literature focuses on the comparison 
between the APTIMA mRNA test and the Hybrid Capture II DNA test, two promising 
tests approved by the FDA.   
 
Method:  An exhaustive literature search was conducted in Medline, CINAHL , Web of Science, Google Scholar, and EBMRmultifile using the search terms 
papilomaviridae, uterine cervical dysplasia, RNA, and sensitivity and specificity in combination and alone as well as terms known to be synonymous.  No limitations were placed on the search.  Excluded were articles that assessed HPV screening in the HIV population, non-cervical methods of screening, screening conducted on self-collected samples, and those studies not utilizing both the APTIMA HPV mRNA assay and the Hybrid Capture II test, as well as articles not written in the English language.  
 
Results:  Seven accuracy studies were included based on the inclusion and exclusion 
criteria delineated in the methods section.  All studies utilized histology as the gold 
standard of comparison.  All studies included showed the Aptima HPV mRNA assay 
(AHPV) to have comparable sensitivity to Hybrid Capture II DNA test (HC2) and 
statistically better specificity for detection of clinically significant cervical lesions 
classified as CIN2+.  Four of the studies compared the AHPV to both HC2 and liquid 
based cytology (LBC) and demonstrated AHPV and HC2 to have better sensitivity for 
CIN2+ than LBC. 
 
Conclusion:  This systematic review clearly shows that the AHPV assay could play a 
promising role in the future of cervical cancer detection.  The AHPV maintained high 
sensitivity, similar to the HC2, while showing improved specificity.   
 
Keywords:  papillomaviridae, papillomavirus, uterine cervical dysplasia, cervical 
intraepithelial neoplasm, uterine cervical neoplasm, RNA, and sensitivity and 
specificity 
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The Efficacy of the Aptima HPVmRNA Assay in Comparison to the Hybrid 
Capture II:  a systematic review 
BACKGROUND 
 Cervical cancer remains a leading cause of morbidity and mortality worldwide 
with the World Health Organization (WHO) reporting approximately half a million 
women diagnosed with cervical cancer and over a quarter million deaths attributed to this 
preventable disease each year.   Large disparities between developing/developed nations 
as well as rural/urban demographics are noted. The largest incidence occurs in 
developing countries where screening programs are not currently in place due to a lack of 
infrastructure and trained personnel inhibiting initiation of traditional cytology based 
screening (see Figure 1).1 This elucidates the further need for both refinement of current 
screening mechanisms and feasible options for areas without such systems in place. 
 Despite all of the advances made in industrialized nations, the American Cancer 
Society reported that in 2011 approximately 12 000 US women were diagnosed with 
cervical cancer leading to over 4000 deaths.2 Over $570 million of our annual healthcare 
burden is attributed to the diagnosis and treatment of pre-malignant lesions such as the 
estimated 412 000 CIN1 and CIN2/3 lesions and upwards of 3 million ASCUS cytologies 
which require further diagnostic workup.3  
 The American College of Obstetricians and Gynecologists (ACOG) and the US 
Preventive Services Task Force currently recommend screening intervals of cytology 
every 2-3 years and HPV co-testing after age 30.    Cytology based methods of screening 
were introduced over 50 years ago and have changed little over time.  There are several 
well established weaknesses with the standard cytology based methods such as results are 
dependent on adequate collection of the specimen, interpretation is subjective in nature 
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and labor intensive, and the fact that a low negative predictive value requires frequent 
screening.  In addition, liquid based cytology testing has been shown to have a sensitivity 
of around 76% and a specificity of around 86% leading to many cases of cervical cancer 
being missed or interpreted as negative.4-6 
 It is well accepted that the human papillomavirus (HPV) is a necessary causative 
factor in the development of cervical cancer.  HPV deoxyribonucleic acid (DNA) is 
detectable in 99.7% of cervical cancer cases.7 Multiple randomized controlled trials and 
studies have shown that HPV DNA testing is significantly more sensitive than traditional 
cytology. 8-10 In addition, studies have shown that a negative HPV test infers a longer low 
risk period of developing CIN2+/cancer than cytology.11 This makes HPV DNA tests an 
attractive possibility in cervical cancer screening.   
 However, HPV DNA tests have a lower specificity when compared to traditional 
liquid based cytology12, 13 because they look for the presence or absence of a gene.  The 
non-selective nature of the DNA test predilects its inability to distinguish between 
transient infections, which clear on their own, and persistent infections, which are linked 
to potential malignant changes.  It is thought that up to 90% of HPV infections regress 
spontaneously without treatment, most within the first twelve months.14 It is those 
persistent infections, in which the viral DNA is integrated, which pose the most risk of 
progression to carcinoma.  The challenge lies in how to discriminate transient infections 
from persistent infections, thereby improving the HPV test specificity.  
 More recent insight into HPV’s lifecycle and the events that lead to cellular 
transformation have guided research in potential biomarkers that could provide both a 
sensitive and specific mechanism of identifying pre-malignant changes and improve 
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screening accuracy, either as an adjunct to current screening, or as a primary method.  In 
2006, the European Research Organization on Genital Infection and Neoplasia 
(EUROGIN) identified four main areas of research for appropriate biomarkers.  One of 
the most promising advances identified was the detection of E6 and E7 mRNA.15   
 Two viral oncoproteins, E6 and E7, have been found to have well delineated roles 
in the neoplastic transformation of endocervical cells.  Expression of E6 and E7 
oncoproteins only occurs with persistent HPV infections and results in events leading to 
the degradation of the tumor suppressor gene products, P53 and pRb, and ultimately to an 
unregulated cell cycle.16, 17 This promising advance could lead to a more specific HPV 
test for detection of pre-malignant or malignant cervical lesions.   
 The APTIMA HPV (AHPV), which was recently approved by the FDA on 
October 28, 2011 and is now approved in 47 countries, tests for the E6/E7 mRNA of 14 
high-risk HPV types.  It is approved to run on Gen-Probe’s fully automated system 
decreasing interpretation variability.  The FDA approved the use of AHPV as an 
adjunctive test to the pap in women 30 or older and for triage of ASCUS cytology in 
women 21 and older in accordance with the current cervical cancer recommendations 
based on the CLEAR trial, which analyzed 11 000 women presenting for routine 
screening at 18 US clinics.18 
 As new evidence becomes available and research guides evidence based medicine 
practices, it is likely that the face of cervical cancer screening will change over time.    
Randomized control trials have shown HPV testing to be a hopeful direction for the 
primary screening role when combined with reflex cytology for triage of positive 
results.12, 13, 19, 20 This reversal of the traditional roles provides the benefit of increased 
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sensitivity.  A five year observational study of 331 818 women, 30 years or older, in the 
United States who were tested with both the HPV DNA test and liquid based cytology 
determined that based on the five-year incidence of CIN3 and cervical cancer, HPV 
testing followed by cytology triage would efficiently detect more cases of CIN3 and 
cancer than cytology alone.20 Preliminary models assessing cost effectiveness seem to 
support the use of HPV testing in cervical cancer screening as well.21 The question which 
remains is: would an HPV test, such as one that utilizes E6/E7 mRNA detection, provide 
both increased sensitivity and adequate specificity to warrant changing practice habits? 
 This systematic review addresses the question of whether the Aptima HPV 
mRNA test might offer the desired improved specificity while maintaining high 
sensitivity in comparison to HPV DNA testing or liquid based cytology, possibly guiding 
the role of this hopeful biomarker.  E6/E7 mRNA tests, such as Aptima, could play a role 
in the screening of women for cervical neoplasms in both the industrialized and 
developing nations, representing the next step forward in diagnosis and prevention of 
cervical cancer.   
METHODS 
   An exhaustive literature search was conducted in Medline, CINAHL , Web of 
Science, Google Scholar, and EBMRmultifile using the search terms papillomaviridae, 
uterine cervical dysplasia, RNA, and sensitivity and specificity in combination and alone.   
Scientific terms that were synonymous with these terms, including, cervical 
intraepithelial neoplasm, uterine cervical neoplasm, and papillomavirus were searched to 
prevent the omission of any relevant articles.   The references of selected articles were 
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screened for the presence of any articles not produced in the original literature search.  
No limitations were placed on the search. 
Articles not written in the English language were excluded, duplicates were 
removed and then titles and abstracts were screened for relevancy.  Excluded were 
articles that assessed HPV screening in the HIV population, non-cervical methods of 
screening, screening conducted on self-collected samples, and those studies not utilizing 
both the APTIMA HPV mRNA assay and the Hybrid Capture II test.  (See Figure 2.) 
 The articles reviewed were critically appraised using the GRADE22 approach to 
evaluate their validity.  Each article was placed into a category, high, medium, low and 
very low, based on the quality of evidence.  
RESULTS 
Seven accuracy studies23-29 were included in this review based on the 
inclusion/exclusion criteria delineated in the methods section. Three prospective, blind 
comparison to a gold standard studies23-25 and four cohort studies with blind comparison 
to the gold standard26-29.  All studies included showed the Aptima HPV mRNA assay 
(AHPV) to have comparable sensitivity to Hybrid Capture II DNA test (HC2) and 
statistically better specificity for detection of clinically significant cervical lesions 
classified as CIN2+.  Four of the studies23-26 compared the AHPV to both HC2 and liquid 
based cytology (LBC) and demonstrated AHPV and HC2 to have better sensitivity for 
CIN2+ than LBC.  
Monsonego et al 
  Monsonego et al23 recently published a prospective study with a blind 
comparison to histology as the gold standard performed on a large screening based 
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population in Paris, France.  From April 2008 to February 2009, women age 20-65 
presenting for routine screening at seventeen gynecological offices were invited to 
participate in the study with a protocol in accordance to the Declaration of Helsinki and 
approved by the Independent Ethics Committee.   Patient demographic data was 
evaluated and included.  Exclusion criteria were set as prior hysterectomy, current 
pregnancy, or abnormal cytology results in the past six months.  In total, 5006 women 
were enrolled with 525 women excluded:  3 for lack of consent, 53 for protocol 
violations, and 469 for invalid cytology results.23   
 The final set of eligible participants (n=4481) had an additional 52 women 
excluded due to absence of one or more of the HPV tests.  This resulted in a total of 4429 
women receiving a liquid based cytology sample collected with a Cervex-Brush and 
placed in PreservCyt medium.  A ThinPrep liquid pap test along with both HC2 and 
AHPV tests were then performed.23   
 The LBC sample was analyzed at the Laboratoire Lavergne, Paris, France and 
classified using the 2001 Bethesda System by blinded cytopathologists.  All abnormal 
results and a random 14% of normal results were blindly double-read by an independent 
external reviewer.23  
 The LBC sample was then divided into two equal portions and tested with both 
the HC2 and AHPV assays in alternating sequence in groups of 2500 according to 
manufacturer’s instructions at a central laboratory.  All persons performing these tests 
were blinded to the LBC results.23  
 Women positive for any of the above tests and 14% of women negative for all 
three, selected via a random sample, were referred for colposcopy.  For colposcopies in 
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which lesions were identified, biopsies were collected from areas of identified 
abnormalities as well as each quadrant of the transformation zone.   Those women with a 
positive screening test but negative colposcopy received a biopsy at both 12 and 6 
o’clock.  No biopsy was performed on women who were negative for all three screening 
tests with a negative colposcopy.    All biopsies were examined by a histopathologist, 
blinded to the HPV results at a central laboratory, and re-examined by an independent 
reviewer who was also blinded to the HPV results. 23  
 Demographic differences and screening test results by age were assessed utilizing 
the Wilcoxen rank sum test and Fisher’s exact test.  Sensitivity, specificity and predictive 
values were estimated using maximum likelihood adjusted for verification bias via 
extending the proposed method for verification-bias adjustment estimators by Zhou et al 
and Roldan-Nofuentes et al to accommodate all three screening tests.  CIN2+ and CIN3+ 
were used as endpoints for calculations.23   
 Monsenego et al23 determined that out of 4481 LBC cytology samples there were 
723 women with normal cytology results via LBC who received histology results: 278 
from the random negative sample and 445 who were positive for one or more of the HPV 
screening tests.  Of these 723 cytological negative samples:  24 CIN2, 6 CIN3, and one 
adenocarcinoma in situ were identified.  All 31 of these clinical diseases which cytology 
failed to detect were from the group screening positive for one of the HPV tests.  They 
also determined that in women with abnormal cytology, approximately six colposcopies 
would need to be performed to find one CIN2+ lesion and approximately twenty-one to 
find one CIN3+ lesion.23 
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 In addition, they determined that both HC2 and AHPV performed with high 
sensitivity in detection of CIN2+ clinical lesions (HC2 96.7% and AHPV 92.0%) and 
were more sensitive than LBC (69.1% p<0.006).  AHPV was significantly more specific 
than HC2 in detection of CIN2+ lesions (91.8% vs. 86.4%, p<0.001) and similar in 
specificity to LBC (91.8%).  (See Table 1.) 
Wu et al 
 Wu et al25 performed a prospective cohort study utilizing 2098 unscreened or 
poorly screened women age 25-59 years from Shenzhen, China according to a protocol 
approved by the institutional review board from the Peking University Shenzhen Hospital 
and the Cleveland Clinic (Cleveland, Ohio).  Exclusion criteria were set as prior 
hysterectomy, current pregnancy, history of pelvic radiation, or cervical cancer screening 
in the past three years. Demographic characteristics were collected and reported. 25 
  Cervical specimens were collected in SurePath liquid for cytology and PreservCyt 
medium for HPV testing via HC2 and AHPV.  Three women with missing results and 95 
women who were lost to follow up were excluded from the final data set of 2000 women.   
Women positive for cytology or either of the HPV tests were referred for colposcopy and 
biopsy of any area of abnormalities detected and at 2, 4, 8 and 10 o’clock positions of all 
normal appearing quadrants followed by endocervical curettage.25   
 All tests were performed in accordance to manufacturer’s instructions.  HC2 tests 
were performed at the Royal Ladies Gynecology Clinic by individuals blinded to all other 
test results.  AHPV tests were performed by Gen-Probe at a remote site in a blinded 
fashion.  Cytology and pathology results were performed by specialists blinded to all 
HPV test results at the Peking University Shenzhen Hospital in Shenzhen.25 
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 Wu et al25 concluded that when the performance of all three screening 
mechanisms was evaluated using the histological diagnosis of CIN2+ as a clinical 
endpoint, the sensitivities of LBC, HC2, and AHPV were determined to be 66.7%, 88.9% 
and 100%, (see Table 1) respectively, with a statistically significant difference between 
AHPV and LBC (p<0.004 by the McNemar test).  In addition, it was noted that there 
were 15 cases of CIN3+ identified: 10/15 detected by LBC, 14/15 by HC2, and 15/15 
detected by AHPV.  The specificities of LBC, HC2, and AHPV were calculated at 
95.5%, 84.5%, and 91.2%, respectively.  (See Table 1.) These results led them to draw a 
final conclusion that the high sensitivity and specificity of the Aptima test make this 
assay a candidate for use in primary screening for the detection of cervical disease noting 
that it can be run on Gen-Probe’s existing STD platform for Gonococcus and 
Chlamydia.25 
Clad et al 
 In the retrospective, referral based cohort conducted by Clad et al,26 the sensitivity 
and specificity of AHPV, HC2, and LBC were determined, to compare each test’s ability 
to detect high-grade cervical lesions (CIN2+).   In total, 492 specimens were collected 
from women referred to the Universitaets-Frauenklinik in Freiburg, Germany for 
colposcopy due to an abnormal screening pap.  Samples were collected during 
colposcopy using ThinPrep in PreservCyt medium and stored for up to three years at 
room temperature.  Exclusion criteria were identified as current pregnancy, missing 
histology results or inadequate specimens, and vaginal or vulvar dysplasia.26   
 Colposcopies were performed by one physician and images of findings were 
digitally documented.   Patients with positive findings were subjected to biopsy and later 
 16 
treated according to standard of care.  Patients with abnormal pap results but no visible 
lesions were subjected to loop electrosurgical excision procedure (LEEP).  Those with a 
normal pap result and a normal colposcopy were not subjected to biopsy and considered 
“histology normal”.26 
 All conventional and LBC specimen evaluations were carried out at the Institute 
of Pathology – University of Freiburg, Germany and then residual samples stored for 
future HPV testing.  The HC2 test and AHPV test were performed blinded to both the 
cytology and histology results at the University of Heidelberg, Germany and Gen-Probe 
Incorporated, San Diego, CA according to manufacturer’s instructions.26   
 Clad et al26 concluded that the sensitivity of the three screening mechanisms for 
detection of CIN2+ lesions, when calculated by comparison with histology, were LBC 
(84.90%), HC2 (91.30%), and AHPV (91.70%). The AHPV assay had the highest 
specificity at 75.00% followed by LBC 66.30%. (See Table 1.)  It is noted that both 
AHPV and HC2 had a statistically significantly higher sensitivity (p=0.0041 for AHVP 
and p=0.0094 for HC2) than cytology.  In addition, AHPV had a significantly higher 
specificity than HC2 (p<0.001) and cytology (p=0.0163) for the detection of CIN2+. 26  
 After the study was complete, CIN2 lesions were detected at the follow up of two 
patients with negative HC2, colposcopy, and cytology results but a positive AHPV test.  
In addition, one pregnant woman with an abnormal pap returned two months after 
delivery.  In this woman, the AHPV test remained positive while her cytology and HC2 
test returned to negative.  An extensive CIN3 lesion was detected 2 years later.26   
 Overall, the conclusion was drawn that the AHPV assay is able to detect HPV 
high-risk mRNA in retrospective clinical LBC with high correlation to cervical disease. 
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In addition, the AHPV is significantly more sensitive and specific than cytology.  Clad et 
al concluded that the AHPV assay performs better than HC2 and LBC in a referral-based 
population.26 
Ratnam et al 
 Ratnam el al28 compared the AHPV and HC2 assays to histology in a referral 
population of women from five clinics in five providences across Canada for a 
longitudinal cohort study.  Women aged 15 years and older with a cytological 
abnormality referred for colposcopy in the past two years who had not sought treatment 
were eligible for the referral group.  In addition, another set of women presenting for 
routine screening were included.28  
 Upon enrollment, all women had a single cervical specimen collected with 
ThinPrep in PreservCyt medium, which was evaluated at the Public Health Laboratory, St 
John’s, Newfoundland, Canada using the 2001 Bethesda system.  Residual fresh 
specimens were used for testing of AHPV and HC2 within two weeks of collection 
according to the manufacturer’s instructions.  All researchers and individuals performing 
the tests were blinded to the results obtained from cytology, colposcopy, and histology.28   
 Colposcopy and, if indicated, biopsy were performed with histology being read by 
pathologists at each respective study site.  Results of CIN2+ served as clinical endpoint 
for data analysis.  All pathologists were blinded to HPV results.28   
 Data were analyzed to determine the clinical performance of each test using 
histology as gold standard.  Sensitivity and specificity were calculated using contingency 
tables and the 95% confidence intervals computed using the binomial method.  
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McNemar’s chi-square test was used to test the differences between sensitivity and 
specificities.28   
 Ratnam et al28 determined that AHPV had a sensitivity of 96.3% for CIN2+ 
compared to HC2 which had a sensitivity of 94.3% with no statistical significance 
between the two modalities.  AHPV had a specificity of 43.2% compared to HC2’s 
specificity of 38.7%  (p<0.05).  (See Table 1.)  In addition, AHPV detected all 13 cases 
of cervical cancer, whereas HC2 only detected 12/13.  AHPV would reduce colposcopy 
referrals by approximately 6.0% if used as adjunct to ASCUS cytology in the place of 
HC2.  This study concluded that the AHPV test has the potential to serve as a feasible 
option for both primary cervical cancer screening and the triage of borderline cytology 
diagnoses.28  
Dockter et al  
 Dockter et al29 presents a study to assess the clinical performance of AHPV 
compared to HC2 in the detection of high-risk HPV and relevant disease (CIN2+) in 800 
specimens collected with ThinPrep pap in PreservCyt medium from women referred for 
colposcopy in Paris, France.  Colposcopies were performed and biopsies obtained from 
any visible lesions.  No biopsies were collected from those subjects with a negative 
colposcopy and considered disease negative.29 All testing was performed in a blinded 
fashion (J. Dockter, e-mail communication, January 26, 2012). 
 The AHPV was run on both the direct tube system (DTS) and the fully automated 
TIGRIS system according to manufacturer’s instructions.  The HC2 was also run from 
the same clinical specimens in accordance with manufacturer’s instructions.  The 
sensitivity, specificity, positive predictive value and negative predictive value were 
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determined for both the AHPV and the HC2 using histology results of CIN2+ and CIN3+ 
as clinical endpoints.  95% Confidence intervals were calculated with the Score method 
and McNemar chi-square test was utilized to determine p values.29   
 AHPV assay was determined to have a clinical sensitivity for detection of CIN2+ 
of 90.8% (84.9-94.5) on both the DTS and the TIGRIS system with no statistically 
significant difference compared to the 95.0% (90-97.6) for the HC2 test with a p>0.05, 
while the specificity of the AHPV at 55.4-56.2% (51.4-60.1) was statistically 
significantly more specific than the HC2’s performance of 47.4% (43.5-51.4) p<0.0001.  
(See Table 1.)  The observed decrease in specificity of the HC2 test equates to as many as 
54 colposcopy referrals in false positive specimens with normal colposcopy findings 
compared to the AHPV assay.  Overall, based on the study, Dockter et al believe that the 
AHPV assay was both highly sensitive and specific for detection of high-grade cervical 
lesions in the tested referral population.29 
Szarewski et al 
 This cohort study was conducted by Szarewski et al24 to compare the sensitivity 
and specificity of several tests including the AHPV and HC2 for detection of high-grade 
CIN2+ as diagnosed by biopsy and histopathology in 999 women referred for colposcopy 
for abnormal cytology between August 2005-January 2007 in London, England.  
Exclusion criteria were set as current pregnancy, previous treatment of CIN, and 
hysterectomy.  Non-eligible women and excluded women were identified clearly in the 
report.  The study protocol was reviewed by the local research ethics committee.24  
 Before colposcopy was performed, a cervical sample was obtained with the 
ThinPrep system in PreservCyt medium, which was used for LBC and HPV testing.  The 
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LBC samples were analyzed at The Doctors’ Laboratory.  HPV testing was then 
performed according to manufacturer’s instructions at the Cancer Research UK except 
for the AHPV test, which was carried out by the Gen-Probe.  All laboratories performing 
molecular testing were blinded to the cytology and histopathology results.  All 
histopathology results were reviewed locally by Dr. Hilary Buckley or Dr. Christine 
Bergson, who were both blinded to all HPV test results.24   
 Statistical analyses were made using Stata 9.2 from Stata Corp.  The gold 
standard of histologically confirmed CIN2+ was used for clinical endpoint calculations of 
sensitivity, specificity, positive predictive value, and negative predictive value for each 
test along with 95% exact binomial confidence intervals.  Analyses indicated that the 
AHPV had a sensitivity of 95.2% for CIN2+ whereas the HC2 had a sensitivity of 99.6%, 
but that the AHPV had the highest specificity at 42.2% as opposed to HC2’s specificity 
of 38.8%.  The referral pap cytology had a sensitivity of 93.1% and a specificity of 17.8% 
for CIN2+ lesions while the cytology collected on the day of colposcopy had a sensitivity 
of 92.3% and a specificity of 60.8%.24  (See Table 1.) 
 It was concluded that by comparing a wide range of adjunctive tests on the same 
samples, with histology as the gold standard, that both the AHPV and the HC2 had high 
sensitivity. Furthermore, they are unlikely to miss significant clinical disease, but the 
AHPV assay had better specificity correlating to fewer false positives and unnecessary 
follow-up.24   
Reuschenbach et al 
 In this cross-sectional cohort by Reuschenbach et al,27 the AHPV and HC2 tests 
were evaluated on 275 liquid based cytology specimens from women who attended the 
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dysplasia outpatient clinic in Freiburg, Germany between 2005 and 2007.  A total of 316 
women were enrolled and based on exclusion criteria of invalid results in one or more of 
the tests, pregnancy, and vulvar or vaginal carcinomas; 275 were included in the final 
study.  The median age of those enrolled was 36 years old.  Colposcopy was performed 
on all women during which cytology samples were collected and placed in PreservCyt 
medium and biopsies taken from all but 38 women.   All tests were performed in 
accordance to manufacturer’s instructions.  The gold standard of histologically confirmed 
CIN2+ was used as clinical endpoint for statistical analysis.27   
 Rueschenbach et al27 determined that for the cohort of women selected, the 
sensitivity of AHPV was 88.4% (82.3-92.7) vs. 91.5%(85.8-95) for HC2.  In addition, 
they determined that AHPV had better specificity than HC2 for detection of CIN2+, 
63.4% vs. 71.2% respectively.27  (See Table 1.) 
 It was concluded that AHPV had a similar sensitivity for detection of CIN3+ and 
slightly lower for CIN2+ when compared to HC2, but much higher specificity for 
detection of both endpoints.  Thus, an enhanced diagnostic profile was observed by the 
use assays targeting oncogenic proteins, E6 and E7, such as AHPV.27 
DISCUSSION 
 This systematic review clearly shows that the AHPV assay could play a promising 
role in the future of cervical cancer detection.  A summary of findings is presented in 
Table 1, which shows AHPV to have a similar sensitivity to the widely accepted HC2 
DNA test in both the screening population23, 25 and the referral population.24, 26-28, 30 
AHPV sensitivity ranged from 88.4%-92.0% (95%CI, 82.3-100) compared to HC2 
88.9%-99.6% (95% CI, 70.8-100) across the seven analyzed studies.23-30 In Monsenego et 
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al, it was noted that of a subset of 15 CIN3 lesions, the AHPV detected 15/15 compared 
to 14/15 for HC2 and only 10/15 for LBC.23   This is consistent with other studies, which 
have shown HPV mRNA tests to have a sensitivity similar to HPV DNA tests while 
offering improved specificity.19, 31-33 Most interestingly, AHPV showed improved 
specificity over the HC2 test in all seven studies included in this review, further 
strengthening the test’s future role in medical decision-making.23-29 AHPV had a 
specificity ranging from 91.2%-91.8% with narrow 95% confidence intervals between 
89.8-92.6 for the large screening-based populations of Monsenego et al23 and Wu et al25.  
AHPV also had stronger specificities in the range of 42.2%-75.0% (95% CI, 38.4-80.9)24, 
26-29 for the referral based populations of the other included studies.   Overall, these 
comparisons show that AHPV mRNA assay performs strongly when compared to the 
HC2 HPV DNA test.  The increase in specificity over HPV DNA testing equates to fewer 
false positives, saving both the cost of workup and the harms related to unnecessary 
procedures.  
 In four of the studies reviewed23-26, the AHPV assay was compared to both HC2 
and liquid based cytology.  These studies concur with the previous meta-analysis12, 
comparing HC2 DNA testing to LBC, that HPV DNA testing is more sensitive than LBC, 
but lacks specificity.  Interestingly, two studies point to the AHPV mRNA assay and 
LBC having similar specificities (91.8%vs 92.7% in Monsenego et al23) and (95.5% vs. 
91.2% in Wu et al25) in the screening-based population.  In fact, the confidence intervals 
overlap in both of these studies precluding any determination of significance of the noted 
difference.  Three of the studies using referral-based populations did not report the 
sensitivity/specificity calculation for LBC.27, 28, 30 Two studies, Clad et al26 and Szarewski 
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et al,24 reported the AHPV to have an even better specificity when compared to LBC for 
detection of CIN2+ lesions in the referral population.    
 Likelihood ratios were calculated (see Table 3) and demonstrated that AHPV has 
a LR+ greater than 10 in both the large population based studies of Monsonego et al23 and 
Wu et al25 making it a viable test to rule cervical neoplasm in, as well as a LR- ratio of 
less than 0.1 making it viable to also rule out cervical neoplasm.  This strengthens the 
evidence to support the use of AHPV mRNA tests in the screening population.    As seen 
in Table 3, AHPV performed quite well compared to HC2 and LBC in all of the studies 
included with larger LR+ correlating to stronger diagnostic ability. 
 Likelihood ratios were graphed34 for all studies included in order to better 
compare the tests overall predictive value.  (See Figure 3.)  It can be concluded that 
AHPV performed superior to LBC in three of the four studies21,23,24  which reported LBC 
sensitivities and specificities and was better at detecting the presence of disease in the 
other study, Wu et al22.   AHPV also performed superior to HC2 in three of the 
studies22,23,25 and better at detecting the absence of disease in the other four20,21,24,26.   
Limitations 
 Limitations of all included studies were reviewed.  (See Table 2.)  Both 
population-based studies23, 25 were well done in a prospective manner: providing adequate 
sample numbers, control groups, comparison against the gold standard of histology, and 
proper blinding.  The referral-based studies varied in strength of design.  All studies were 
subject to indirectness as they all utilized the outcome of CIN2+.   This is a minor area of 
indirectness as CIN2+ is also the threshold for medical intervention and therefore still a 
patient important outcome.   
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 Monsenego et al23 had a sample size of 4481 women presenting for routine 
screening with a randomly selected 14% of negative samples (491) used as the control 
group.  A larger control group would have been preferential to maintain balance in the 
two groups.  All results were adjusted for verification bias and mechanisms for multiple 
reviewers and resolution of discordant results were made transparent.  Comparisons were 
made utilizing the gold standard of biopsy and histological diagnosis. No areas of bias 
could be identified.  
 Similarly, Wu et al25 utilized selection based on routine screening, which allowed 
for a representative subject group as identified in the demographic data provided.  The 
total subject pool was comprised of 2098 women who received biopsies in five cervical 
areas if positive for any of the three screening tests.  Proper blinding was maintained. 
Those women who were negative for cytology and both HPV tests were considered the 
control.  While it would have been preferential to have a portion of these women undergo 
biopsy as the gold standard, this does not greatly influence the overall strength of the data 
collected.  In addition to direct statistical comparisons, the partial areas under the receiver 
operating curves were compared. 
 Clad et al26 performed a study utilizing a referral-based population, inclusion and 
exclusion criteria were identified and blinding was adequately performed. This group of 
women may not be representative of the average woman making any conclusions about 
the sensitivity and specificity of the tests for screening impossible.  But, this study does 
allow for the analysis of the performance in a triage scenario and also allows for a larger 
variation of disease to be represented.  In addition, only 424 specimens were analyzed.  A 
larger sample size would have made the evidence stronger.  Three main limitations were 
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identified:  1) specimens were stored at room temperature for up to three years before 
testing but not a consistent time frame from specimen to specimen 2) no biopsies were 
taken from patients with a normal colposcopy and a normal cytology screening 3) HPV 
tests were run later, no colposcopies were done for those specimens that were only 
positive by HPV.   
 Ratnam et al28 was overall fairly well conducted but did have some 
inconsistencies identified, such as not all subjects had histology results and those who 
were HPV positive but cytology negative did not receive a colposcopy due to the design 
of the study.  In addition, the outcome of CIN2+ was used, which as discussed above, is 
only a minor area of indirectness.   
 In the study performed by Dockter et al29, an area of bias identified was that J. 
Dockter is employed by Gen-probe.   The outcome of CIN2+ was utilized and those with 
negative colposcopy were not subjected to biopsy.  Szarewski et al24 also faced similar 
limitations.  Reuschenbach et al27 also utilized CIN2+ as an outcome resulting in minor 
indirectness as discussed above,  in addition after exclusion criteria were applied the total 
sample size studied was only 275 participants resulting in wider confidence intervals and 
an identified area of possible imprecision.   
 The quality of each study was assessed utilizing the GRADE assessment tool.  
(See Table 2.)  Monsonego et al23 and Wu et al25 remained at high quality while the other 
included studies were downgraded to moderate24, 26, 28or low27, 29based on limitations 
identified.  Overall the quality of evidence of this body of literature is moderate.  (See 
Table 2.) Showing that further research is needed, but unlikely to drastically change 
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confidence in these results.  Instead, further research will more fully support and refine 
the evidence for the use of HPV screening in the detection of cervical neoplasms. 
Conclusions 
 Reviews such as this illuminate the need for further research to determine both the 
long-term viability and cost effectiveness of utilizing HPV mRNA tests, such as AHPV, 
in the detection of cervical lesions in a primary screening role for cervical cancer.  
Randomized controlled trials as well as longitudinal studies that evaluate the overall 
effect on, not just the outcome of CIN pre-malignant lesions, but on the actual morbidity 
and mortality of cervical carcinoma are needed.  Also promising, is the possibility of 
utilization of self collected specimens for community based screening programs in areas 
of the world with the highest cervical cancer mortality rates and the lack of infrastructure 
to support traditional screening programs.   
 These findings are relevant in our decision making in order to provide the best 
patient care, by practicing evidence based medicine, we are likely to change the current 
practice of using the HC2 HPV DNA test for triage of borderline cytology, as well as in 
HPV co-testing of women age 30 and older, to the use of AHPV mRNA assay.  Both the 
AHPV and HC2 tests are approved in those situations, but the AHPV provides both 
improved specificity while maintaining high sensitivity.   
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Table 1 Summary of Findings 
 
STUDY: Study Type Population Age 
Range 
Comparison Sensitivity (95% CI) 
AHPV     HC2      LBC 
Specificity (95% CI) 
AHPV     HC2         LBC 
  Conclusions: 
Monsenego, et 
al23 
Accuracy Study 
– Prospective, 
Blind 
Comparison to 
Gold Standard 
4429 ♀presenting for 
routine screening at 
gynecology office in Paris, 
France between 8/08-2/09 
20-65 AHPV mRNA, 
HC2 DNA, and 
thin prep pap 
cytology vs. 
histology 
92.0% 
(86.4-
97.6) 
 
96.7% 
(92.6-
100) 
 
69.1% 
(60.0-
78.1) 
 
91.8% 
(91.0-
92.6) 
 
86.4% 
(85.4-
87.4) 
 
91.9% 
(91.1-
92.7) 
 
AHPV was more sensitive than LBC 
by >25% while maintaining similar 
specificity.   
Wu, et al25 Accuracy Study 
– Prospective, 
Blind 
Comparison to 
Gold Standard 
2000♀ from medically 
underserved Luohu district 
in Shenzhen, China 
 
25-59 AHPV mRNA, 
HC2 DNA, and 
thin prep 
cytology vs. 
histology 
100% 
(87.2-
100) 
 
88.9% 
(70.8-
97.6) 
66.7% 
(46.0-
83.5) 
91.2% 
(89.8-
92.4) 
84.5% 
(82.8-
86.1) 
95.5% 
(94.5-
96.4) 
AHPV was more sensitive than LBC 
by >25% while maintaining similar 
specificity.   
Subset CIN3 cases n=15 
AHPV detected 15/15 (100%) 
HC2 detected 14/15 (93.3%) 
LBC detected 10/15 (66.7%) 
 
      
Clad, et al26 Accuracy 
Study- 
Retrospective, 
Blind 
Comparison to 
Gold Standard 
385 ♀referred to 
Universitaets-Frauenklinik 
Freiburg, Germany 
colposcopy  
NR AHPV mRNA, 
HC2 DNA, and 
thin prep 
cytology vs. 
histology 
91.7% 
(87.6-
94.5) 
91.3% 
(87.1-
94.2) 
84.9% 
(80.0-
88.9) 
 
75.0% 
(68.0-
80.9) 
61.0% 
(53.6-
68.0) 
66.3% 
(58.9-
72.9) 
AHPV is significantly more sensitive 
and more specific than cytology and 
similar sensitivity to HC2 with higher 
specificity for detection of CIN2+ 
Subset of cervical cancer cases n=13 
AHPV detected 12/13 
HC2 detected 11/13 
LBC detected 3/13 
    
Ratnam, et al28 Referral based 
longitudinal 
cohort 
1,418 referral cases and 
1,373 routinely screened 
♀from 5 centers in 5 
provinces across Canada 
16-81 AHPV mRNA, 
HC2 DNA vs. 
histology 
96.3% 
(94.4-
98.2) 
94.3% 
(92.0-
96.6) 
NR 43.2% 
(40.2-
46.2) 
38.7% 
(35.7-
41.7) 
NR AHPV is as sensitive as HC2 but 
more specific with the potential to 
serve as a reliable test for primary 
cervical screening or as adjunct for 
triage of abnormal cytology. 
Subset of cervical cancer cases n=13 
AHPV detected 13/13 
HC2 detected 12/13 
   
Dockter, et al29 Referral based 
cohort 
800 liquid pap specimens 
collected from ♀in Paris 
who were referred for 
colposcopy for abnormal 
screening cytology 
NR AHPV mRNA, 
HC2 DNA vs. 
histology 
90.8% 
(84.9) 
95.0% 
(90.1-
97.6) 
NR 56.2%  
(52.3-
60.1) 
47.4% 
(43.5-
51.4) 
NR AHPV has similar sensitivity and 
significantly higher specificity than 
HC2 in detection of CIN2+ clinically.   
Szarewski, et 
al24 
Referral based 
cohort 
953 ♀referred for 
colposcopy in London 
between August 2005-
January 2007 
 
Median 
age 29.9 
range not 
reported 
AHPV mRNA, 
HC2 DNA, thin 
prep pap 
cytology, vs. 
histology 
95.2% 
(92.0-
97.4) 
99.6% 
(98.0-
100.0) 
93.4% 
(89.8-
96.0) 
42.2% 
(38.4-
46.0) 
28.4% 
(25.0-
32.0) 
15.1% 
(12.5-
18.1) 
AHPV has high sensitivity and better 
specificity than HC2 and referral thin 
prep cytology.  Note:  specificity of 
concurrent thin prep cytology taken on 
day of study was 60.8 (55.4-66.1) 
Reuschenbach, 
et al27 
Referral based 
cross-sectional 
cohort 
316 ♀who attended 
University Hospital of 
Freiburg, Germany for 
abnormal cytology or 
follow-up for treatment of 
dysplasia between 2005-
2007 
Median 
age 36, 
range not 
reported 
AHPV mRNA, 
HC2 DNA, thin 
prep pap 
cytology vs. 
histology 
88.4% 
(82.3-
92.7) 
91.5%  
(85.8-
95.1) 
NR 71.2% 
(61.7-
79.2) 
64.3% 
(53.7-
72.1) 
NR AHPV biomarker test yields high 
specificity while maintaining a similar 
sensitivity to HC2 and thus an 
improved diagnostic profile.   
AHPV = APTIMA HPV mRNA test  HC2 = Hybrid Capture II DNA test LBC = liquid based cytology  NR= not reported  CIN= cervical intraepithelial neoplasm 
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Table 2 Quality of Evidence 
 QUALITY ASSESSMENT   
Study Study Design Risk of Bias Inconsistency Indirectness Imprecision Sample Size Quality 
Monsenego, et al23 Accuracy Study – 
Prospective, Blind 
Comparison to Gold 
Standard 
No areas of bias 
identified 
No inconsistencies Minor area of 
indirectness 1 
No serious 
imprecision 
4429 ⊕⊕⊕⊕ 
High 
Wu, et al25 Accuracy Study – 
Prospective, Blind 
Comparison to Gold 
Standard 
No areas of bias 
identified 
No inconsistencies Minor area of 
indirectness * 
No serious 
imprecision 
2000 ⊕⊕⊕⊕ 
High 
Clad, et al26 Accuracy Study- 
Retrospective, Blind 
Comparison to Gold 
Standard 
No areas of bias 
identified 
Minor 
inconsistencies2 3 
Minor area of 
indirectness * 
No serious 
imprecision 
385 ⊕⊕⊕ 
Moderate 
Ratnam, et al28 Accuracy Study- 
Blind Comparison to 
Gold Standard 
No areas of bias 
identified 
Minor 
inconsistencies† ‡ 
Minor area of 
indirectness* 
No serious 
imprecision 
1,418 referral cases  
1,373 screening  ⊕⊕⊕ Moderate 
Dockter, et al29 Accuracy Study- 
Blind Comparison to 
Gold Standard 
Potential areas of bias 
identified4 
Minor 
inconsistencies†  
Minor area of 
indirectness * 
No serious 
imprecision 
800 ⊕⊕ 
Low 
Szarewski, et al24 Accuracy Study- 
Blind Comparison to 
Gold Standard 
Possible areas of bias 
identified5 
No inconsistencies Minor area of 
indirectness * 
No serious 
imprecision 
953 ⊕⊕⊕ 
Moderate 
Reuschenbach, et 
al27 
Accuracy Study- 
Blind Comparison to 
Gold Standard 
No areas of bias 
identified 
Minor 
inconsistencies†  
Minor area of 
indirectness * 
Small amount of 
imprecision noted6 
316 ⊕⊕ 
Low 
OVERALL 
QUALITY OF 
EVIDENCE 
CONCLUSION:   ⊕⊕⊕ 
Moderate 
                                                 
1 Surrogate outcome of CIN2+ was used, considered a minor indirectness as this is also the threshold for medical intervention, which is a patient important outcome. 
2 Biopsy specimens were not taken from those with patients with normal colposcopy and cytology.  
3 The HPV testing was done at a later date and biopsies were not done of those women who were only positive for one of the HPV tests. 
4 J. Dockter employed by Gen-probe 
5 A. Szarewski is on the advisory board of Gen-probe, consultant for Roche, and speaker for Qiagen. The AHPV test was run by Gen-probe for all samples. 
6 After set exclusion criteria were applied, n=275, 95%CI were wider than observed in other studies. 
 
Table 3 Likelihood Ratios 
Study + Likelihood Ratio 
AHPV         HC2         LBC 
- Likelihood Ratio 
AHPV        HC2         LBC 
Monsenego, et al23 11.20 7.11 8.53 .087 .038 .336 
Wu, et al25 11.36 5.74 14.82 .000 .130 .349 
Clad, et al26 3.67 2.34 2.52 .111 .143 .228 
Ratnam, et al28 1.70 1.54 NR .086 .147 NR 
Dockter, et al29 2.07 1.81 NR .164 .105 NR 
Szarewski, et al24 1.65 1.39 1.10 .114 .014 .437 
 
Figure 1:  Incidence of Cervical Cancer World Wide1 
 
 Figure 2:  Search Methodology 
Figure 3:  Likelihood Ratio Graphs  
 
 
0
0.2
0.4
0.6
0.8
1
0 0.2 0.4 0.6 0.8 1
tr
ue
 p
os
iti
ve
 ra
te
 
false positive rate 
Monsonego, et al 
0
0.2
0.4
0.6
0.8
1
0 0.2 0.4 0.6 0.8 1
tr
ue
 p
os
iti
ve
 ra
te
 
false positive rate 
Wu, et al 
0
0.2
0.4
0.6
0.8
1
0 0.2 0.4 0.6 0.8 1
tr
ue
 p
os
iti
ve
 ra
te
 
false positive rate 
Dockter, et al 
0
0.2
0.4
0.6
0.8
1
0 0.2 0.4 0.6 0.8 1
tr
ue
 p
os
iti
ve
 ra
te
 
false positive rate 
Clad, et al 
0
0.2
0.4
0.6
0.8
1
0 0.2 0.4 0.6 0.8 1
tr
ue
 p
os
iti
ve
 ra
te
 
false positive rate 
Ratnam, et al 
0
0.2
0.4
0.6
0.8
1
0 0.2 0.4 0.6 0.8 1
tr
ue
 p
os
iti
ve
 ra
te
 
false positive rate 
Szarewski, et al 
0
0.2
0.4
0.6
0.8
1
0 0.2 0.4 0.6 0.8 1
tr
ue
 p
os
iti
ve
 ra
te
 
false positive rate 
Reuschenbach, et al 
0
0.2
0.4
0.6
0.8
1
0 0.2 0.4 0.6 0.8 1
tr
ue
 p
os
iti
ve
 ra
te
 
false positive rate 
Likelihood ratios graph:  regions of  comparison Recreated from  Biggerstaff 34 
I 
Superior 
II 
Absence 
III 
Presence 
IV 
Inferior 
Key: 
AHPV ρ+ 
AHPV ρ-  
HC2 ρ+ 
HC2 ρ- 
LBC ρ+ 
LBC ρ- 
 
References 
1. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human Papillomavirus and Related 
Cancers in World. Summary Report 2010.Available at: www. who. int/hpvcentre. Accessed January 12, 2012. 
2. American Cancer Society. http://www.cancer.org/Cancer/CervicalCancer/DetailedGuide/cervical-cancer-key-statistics. Available 
at: http://www.cancer.org/Cancer/CervicalCancer/DetailedGuide/cervical-cancer-key-statistics. Accessed January 12, 2012. 
3. Henk HJ, Insinga RP, Singhal PK, Darkow T. Incidence and costs of cervical intraepithelial neoplasia in a US commercially insured 
population. J low genit tract dis. 2010;14:29-36. 
4. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic 
abnormalities: a systematic review. Ann Intern Med. 2000;132:810-819. 
5. Abulafia O, Pezzullo JC, Sherer DM. Performance of ThinPrep liquid-based cervical cytology in comparison with conventionally 
prepared Papanicolaou smears: a quantitative survey. Gynecol Oncol. 2003;90:137-144. 
6. Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol. 1995;141:680-689. 
7. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer 
worldwide. J Pathol. 1999;189:12-19. 
8. Whitlock EP, Vesco KK, Eder M, Lin JS, Senger CA, Burda BU. Liquid-based cytology and human papillomavirus testing to 
screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155:687-697. 
9. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical 
cancer screening. Int J Cancer. 2006;119:1095-1101. 
10. Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: the 
HART study. Lancet. 2003;362:1871-1876. 
11. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical 
cancer screening: joint European cohort study. BMJ. 2008;337:a1754. 
12. Whitlock EP, Vesco KK, Eder M, Lin JS, Senger CA, Burda BU. Liquid-based cytology and human papillomavirus testing to 
screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155:687-697. 
13. Ogilvie GS, van Niekerk DJ, Krajden M, et al. A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical 
cancer screening: trial design and preliminary results (HPV FOCAL Trial). BMC Cancer. 2010;10:111. 
14. Rodriguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on 
persistent infections. J Natl Cancer Inst. 2008;100:513-517. 
15. Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of 
cervical neoplasia. Cancer Epidemiology Biomarkers & Prevention. 2008;17:2536-2545. 
16. von Knebel-Doeberitz M, Syrjanen KJ. Molecular markers: how to apply in practice. Gynecol Oncol. 2006;103:18-20. 
17. Trunk MJ, Wentzensen N, von Knebel Doeberitz M. [Molecular pathogenesis of cervical cancer and its first steps]. Pathologe. 
2005;26:283-290. 
18. FDA. Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf10/P100042b.pdf. Accessed January 8, 2012. 
 33 
19. Burger EA, Kornor H, Klemp M, Lauvrak V, Kristiansen IS. HPV mRNA tests for the detection of cervical intraepithelial 
neoplasia: a systematic review. Gynecol Oncol. 2011;120:430-438. 
20. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human 
papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12:663-672. 
21. van Ballegooijen M, van den Akker-van Marle ME, Warmerdam PG, Meijer CJ, Walboomers JM, Habbema JD. Present evidence 
on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-)effectiveness. Br J Cancer. 
1997;76:651-657. 
22. GRADE Working Group. http://www.gradeworkinggroup.org/index.htm Published 2005-2011. Accessed January 19, 2011. . 
Accessed January, 19, 2011. 
23. Monsonego J, Pollini G, Evrard MJ, et al. Detection of human papillomavirus genotypes among high-risk women: a comparison of 
hybrid capture and linear array tests. Sex Transm Dis. 2008;35:521. 
24. Szarewski A, Ambroisine L, Cadman L, et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women 
with abnormal smears. Cancer Epidemiology Biomarkers & Prevention. 2008;17:3033-3042. 
25. Wu R, Belinson SE, Du H, et al. Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen 
Cervical Cancer Screening Trial I. International Journal of Gynecological Cancer. 2010;20:1411-1414. 
26. Clad A, Reuschenbach M, Weinschenk J, Grote R, Rahmsdorf J, Freudenberg N. Performance of the Aptima high-risk human 
papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology. J Clin Microbiol. 
2011;49:1071-1076. 
27. Reuschenbach M, Clad A, von Knebel Doeberitz C, et al. Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA 
testing to identify high grade cervical dysplasia in women with abnormal screening results. Gynecol Oncol. 2010;119:98-105. 
28. Ratnam S, Coutlee F, Fontaine D, et al. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more 
specific at detecting cervical precancer and cancer. J Clin Microbiol. 2011;49:557-564. 
29. Dockter J, Schroder A, Hill C, Guzenski L, Monsonego J, Giachetti C. Clinical performance of the APTIMA HPV Assay for the 
detection of high-risk HPV and high-grade cervical lesions. Journal of Clinical Virology. 2009;45:S55-61. 
30. Dockter J, Schroder A, Hill C, Guzenski L, Monsonego J, Giachetti C. Clinical performance of the APTIMA HPV Assay for the 
detection of high-risk HPV and high-grade cervical lesions. J Clin Virol. 2009;45:S55-61. 
31. Waldstrom M, Ornskov D. Comparison of the clinical performance of an HPV mRNA test and an HPV DNA test in triage of 
atypical squamous cells of undetermined significance (ASC‐US). Cytopathology. 2011. 
32. Ovestad IT, Vennestrøm U, Andersen L, et al. Comparison of different commercial methods for HPV detection in follow-up 
cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3. Gynecol Oncol. 2011. 
33. Benevolo M, Vocaturo A, Caraceni D, et al. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 
mRNA assay as a triage test for cervical cytology and HPV DNA test. J Clin Microbiol. 2011;49:2643-2650. 
34. Biggerstaff BJ. Comparing diagnostic tests: a simple graphic using likelihood ratios. Stat Med. 2000;19:649-663. 
 
 
